The EDC3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, designed for functional studies of the EDC3 gene. This product provides a heterogeneous pool of gene-disrupted cells, enabling the investigation of EDC3 loss-of-function effects on mRNA decapping and 5′-to-3′ decay pathways. The polyclonal format preserves the genetic diversity generated by CRISPR/Cas9-mediated target-gene disruption, allowing researchers to assess population-level phenotypes without clonal selection bias.
Raji cells are a well-characterized human B lymphocyte line originally isolated from a Burkitt??s lymphoma patient and maintained as an Epstein-Barr virus (EBV)-positive culture. These cells serve as a robust model for B lymphoid biology, particularly in studies of humoral immunity and lymphomagenesis. Their transformed nature and expression of EBV latency genes provide a unique context to examine interactions between viral factors and host post-transcriptional regulatory mechanisms. As a suspension cell line, Raji cells are amenable to a wide range of biochemical and imaging-based assays.
EDC3 is an enhancer of mRNA decapping that acts as a scaffold to stimulate DCP2 activity. It interacts with DCP1A, DDX6, and the LSM1-7 complex to assemble the decapping machinery on target mRNAs within P-bodies. Following decapping, XRN1 degrades the transcript. EDC3 also binds PATL1 and CNOT proteins, linking it to broader RNA turnover networks. Its regulation is influenced by cellular stress and RNA metabolism cues, making it a central node in post-transcriptional gene control.
In B lymphocytes, mRNA stability control is critical for immunoglobulin production, differentiation, and transformation. This Raji EDC3 knockout model allows dissection of EDC3-dependent decay in these processes, especially under EBV-driven gene expression. Although EDC3 itself is not a disease gene, mRNA decay pathway components are linked to cancer and neurodegeneration, making this model valuable for studying how decapping defects alter the B cell transcriptome and lymphoma phenotypes.
These cells are suited for RT-qPCR mRNA stability assays, RNA-seq transcriptomics, and immunofluorescence analysis of P-bodies. Co-immunoprecipitation with antibodies against DCP2, DDX6, or XRN1 evaluates decapping complex integrity. Metabolic pulse-chase and western blotting further quantify mRNA half-lives and decapping factor levels. This polyclonal knockout population is thus ideal for investigating 5′-to-3′ mRNA decay mechanics and EDC3’s role in post-transcriptional control in B lymphoma cells. For support, contact Ascent Research.
